Press Releases and Events

PRESS RELEASES

Press Release | May 23, 2025

Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025

READ MORE
Press Release | May 15, 2025

Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025

READ MORE
Press Release | May 12, 2025

Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | May 8, 2025

Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

READ MORE
Press Release | April 10, 2025

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | March 27, 2025

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly

READ MORE
Press Release | March 10, 2025

Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | February 27, 2025

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

READ MORE
Press Release | February 24, 2025

Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer

READ MORE
Press Release | February 20, 2025

Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences

READ MORE
5 / 25